Rosette-forming glioneuronal tumor: an illustrative case and a systematic review

Caleb P. Wilson, Arpan R. Chakraborty, Panayiotis E. Pelargos, Helen H. Shi, Camille K. Milton, Sarah Sung, Tressie McCoy, Jo Elle Peterson, and Chad A. Glenn

Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
(C.P.W., A.R.C., P.E.P., H.H.S., C.K.M., S.S., T.M., C.A.G.); Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA (J.E.P.)

Corresponding Author: Caleb P. Wilson, BS, Department of Neurosurgery, University of Oklahoma Health Sciences Center, 1000 N Lincoln Boulevard, Suite 4000, Oklahoma City, OK 73104, USA (caleb-wilson@ouhsc.edu).

Abstract

Background. Rosette-forming glioneuronal tumors (RGNTs) are rare, low-grade, primary CNS tumors first described in 2002 by Komori et al. RGNTs were initially characterized as a World Health Organization (WHO) grade I tumors typically localized to the fourth ventricle. Although commonly associated with an indolent course, RGNTs have the potential for aggressive behavior.

Methods. A comprehensive search of PubMed and Web of Science was performed through November 2019 using the search term “rosette-forming glioneuronal tumor.” Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. English, full-text case reports and series with histopathological confirmation were included. Patient demographics, presentations, MRI features, tumor location, treatment, and follow-up of all 130 cases were extracted.

Results. A 19-year-old man with a history of epilepsy and autism presented with acute hydrocephalus. MRI scans from 2013 to 2016 demonstrated unchanged abnormal areas of cortex in the left temporal lobe with extension into the deep gray-white matter. On presentation to our clinic in 2019, the lesion demonstrated significant progression. The patient’s tumor was identified as RGNT, WHO grade I. One hundred thirty patients were identified across 80 studies.

Conclusion. RGNT has potential to transform from an indolent tumor to a tumor with more aggressive behavior. The results of our systematic review provide insight into the natural history and treatment outcomes of these rare tumors.

Key Points
- Rosette-forming glioneuronal tumors have aggressive potential.
- While usually stable after resection, RGNT has been shown to occasionally recur.

The rosette-forming glioneuronal tumor (RGNT) is a rare, low-grade, primary CNS tumor that was first described in 2002 in a case series by Komori et al., in which the authors differentiated RGNT as a distinct entity from the dysembryoplastic neuroepithelial tumor. In 2007, the RGNT was designated as a World Health Organization (WHO) Grade I tumor and described as a slow-growing tumor typically localized to the fourth ventricle and composed of neurocytes that form neurocytic rosettes and glial components similar to those of the pilocytic astrocytoma. In the 2016 WHO classification, the RGNT was again classified as a Grade I tumor and listed under the category of “neuronal and mixed neuronal-glial tumors.” Various other anatomical sites of origin have been reported, including the supratentorial ventricles, pineal gland, hypothalamus, optic chiasm, and spinal cord. Due to the rarity of the RGNT, little is known about its epidemiology and natural history. In this study, we present the...
Importance of the Study
Because the current literature on RGNT is still so limited, little is definitively understood about the epidemiology, anatomical distribution, and even treatment of these tumors, especially since there is a subset of cases with tumors that recurred. Not only does our case and review of the literature unveil the more aggressive clinical course that is possible with these tumors, but it also highlights other unique characteristics.

Case Presentation
Consent
Patient consent was obtained for inclusion in this case report. No identifying details have been disclosed.

History and Physical Examination
A 19-year-old man with a history of autism spectrum disorder and epilepsy who was diagnosed at 19 years of age with a RGNT. His prior MRI demonstrated stable appearance of nonspecific cortical abnormalities of the left temporal lobe that were thought to be related to his epilepsy. His case highlights the natural history of RGNT and presents a tumor in an uncommon anatomical location spanning from the temporal lobe into the basal ganglia extending to involve the cerebellum. In addition, we report the results of a systematic review of the literature pertaining to this rare neoplasm, analyzing key features of RGNT.

Operative Course
On the day of presentation, an external ventricular drain (EVD) was placed to alleviate his hydrocephalus, resulting in mental status improvement. Shortly thereafter, an endoscopic biopsy of the third ventricle lesion along with septum pellucidotomy was performed. The initial evaluation of the pathology demonstrated concern for possible RGNT. However, only the rosette-forming neuronal component of the tumor was present within the nonenhancing third ventricular component. Given these results and the extensive nature of the tumor, a second procedure was planned.

Postoperative Course
His final pathology was consistent with RGNT. The postoperative exam was significant for central fever and autonomic dysregulation likely secondary to the tumor and its resection near the hypothalamus. Attempts were made to wean his EVD. However, a follow-up CT scan showed...
an interval increase in the size of the left lateral ventricle. Symptoms of hydrocephalus continued, and the patient subsequently underwent ventriculoperitoneal shunt placement.

The patient developed a proximal shunt malfunction later that month requiring revision. Gross examination demonstrated tissue buildup within the ventricular catheter fenestrations. Approximately 3 weeks later, the patient again presented with worsening hydrocephalus. Repeat revision of the proximal catheter and shunt valve was performed. At 8 months follow-up, the patient was clinically stable and back to baseline function.

Search Strategy and Collection Criteria

A comprehensive literature review using PubMed and Web of Science was performed through November 2019 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Articles related to RGNTs were identified using the search term “rosette-forming glioneuronal tumor.” Upon removing duplicates, titles and abstracts were screened for relevant articles. English, full-text case reports and series were included. Non-English, abstract-only text, and review articles were excluded. Studies without mention of histopathological confirmation of the RGNT were further excluded. Ultimately, 80 references meeting the selection criteria were included.1,4-82 Patient demographics, presentations, MRI features, tumor location, treatment, and follow-up of all 130 cases (when available) were extracted and summarized. Patient presentations, genetic characteristics of tumors, recurrence analysis, and surgical follow-up are shown in Tables 1–3 and Supplementary Table 1, respectively.

Discussion

Grading

The RGNT is a rare neoplasm, with 130 patients across 80 studies having been identified in the literature. RGNT is currently classified as a benign tumor,3 although many authors report sudden onset of aggressive behavior after prolonged periods of stability. While the most cases of RGNT have an excellent postresection prognosis without any deterioration, the outcome of our illustrative case and systematic review call this indolent nature into question. Our patient’s 6 years of MRIs demonstrate that RGNT has the potential to become rapidly progressive and infiltrative after years of dormancy. Our patient’s tumor showed significant progression on his scan an additional 3 years later. This MRI also revealed a second tumor in the foramen of Monroe. This type of progression is not unique to our case. Of the 91 cases in our review that reported follow-up, 13 demonstrated either recurrence (with or without malignant transformation) or rapid progression/dissemination, totaling 14% of the cases with reported follow-up.

However, there is much inconsistency with regard to the natural history of these tumors. Chiba et al. described a tumor that was only biopsied at first but demonstrated rapid progression of the tumor as well as a new lesion in only 6 months.25 A case described by Cabezas et al. presented with a secondary intraspinal lesion and leptomeeningeal spread of the tumor.21 Silveira et al. also described the dissemination of tumor with drop metastasis in the lumbar spine only 1 month after initial imaging and biopsy of the tumor.69 Other reports have described similarly quick tumor recurrences postoperatively after 4 months and 9 months.74 However, recurrences have also been reported as late as 9 years after initial resection.29 Morris et al. described a particularly aggressive RGNT case in a 6-year-old boy.57 In this case, the tumor progressed and extended into the proximal cervical spinal cord 2 years after initial treatment involving both resection and chemotherapy.57 Another round of chemotherapy did not stop the tumor from further progression, so the tumor was totally resected.57 Unfortunately, the tumor recurred yet again 3 years later.57 There are even 2 cases that describe an RGNT with malignant transformation to glioblastoma after several years.40,49 As a greater number of cases are
reported, it appears that some RGNTs may not be as indolent as previously thought.

**Epidemiology**

RGNT most commonly arises in young adults, as in the case of our 19-year-old patient. However, the youngest reported patient was 4 years old, and the oldest was 81 years old.\(^{25,26}\) The mean age of diagnosis is 29.8 years, which is very similar to earlier findings.\(^{1,11,25}\) However, we noted a much less dramatic gender preference with a female:male ratio of 1.1:1 (68 females and 62 males) in contrast to previous reports describing a female predominance closer to 2:1.\(^{1,5,42,76}\)

**Presenting Symptoms**

Common presenting symptoms of RGNT from our review include headache (71%), ataxia/gait disturbance (25%), vomiting/nausea (24%), visual disturbances (21%), and vertigo/dizziness (16%). Several cases were also found incidentally (13%). Presenting symptoms are displayed in Table 1.

**Imaging Characteristics**

The location of our patient’s tumor makes this case unique from other reports. The original lesion remained stable in the patient’s temporal lobe before progressing to involve the gangliocapsular region, bilateral thalami, tectum, and cerebellum. To our knowledge, only 2 other cases report any involvement of the temporal lobe with RGNT,\(^{56,80}\) and only 6 others had involvement of the cerebellum.\(^{42,43,66,74,76}\) The appearance of the second mass is also notable, especially with its growth into the third ventricle and foramen of Monro. While there have been 13 other reports of RGNT invasion of the third ventricle, to our knowledge, this is the first case to demonstrate invasion and blockage of the foramen of Monro.

**Genetics/Molecular Markers**

The origin of RGNT has yet to be elucidated due to the rarity of the tumor and its indolent course. It has been hypothesized that the neoplasm originates from pluripotent cells of the subependymal plate,\(^{60}\) and Chakraborti et al. showed an evidence of differentiation of stem cells in their case series on RGNT.\(^{83}\) Many genetic mutations have also been found in association with RGNT. The most common genetic marker associated with RGNT is the PIK3CA mutation,\(^{28,29,51,74,84,85}\) FGFR1 mutations have also been implicated in tumor pathogenesis\(^{51,84-86}\) as well as IDH1,\(^{40}\) KIAA1549/BRAF gene fusion,\(^{20}\) PPP1R1A,\(^{51}\) and RNF21.\(^{51}\)

Most cases presented in the literature did not test any molecular markers, and among those that did, most did not test for the now-known genetic associations such as PIK3CA and FGFR1. However, a recent retrospective cohort study was able to obtain tissue samples of 18 different patients with RGNT for comprehensive genomic testing.\(^{84}\) Sequencing of those samples revealed that all 18 contained an FGFR1 mutation with 13 carrying a comorbid PIK3CA mutation. The findings of this study confirm that constitutive activation of the FGFR signaling likely plays a role in a large portion of these tumors. Because constitutive PI3K pathway activation (caused by PIK3CA mutation) has also been implicated in several of the cases in our review as well as in the previously mentioned cohort study, RGNT may commonly be a multiple-pathway disease, which is typically more characteristic of high-grade tumors.\(^{84}\) The findings of this study were not included in our genetics summary table (Table 2) due to publication after our initial database search.

Additionally, a few cases have been found in association with neurofibromatosis type 1,\(^{45,68}\) as well as 2 with Noonan syndrome\(^{45,51}\) and 1 with multiple sclerosis.\(^{70}\) Interestingly, there was one case that presented 4 months after a grade II diffuse astrocytoma.\(^{22}\) Future research in this area may provide further answers about the pathogenesis of RGNT as well as direction for future drug therapy. A summary of the PIK3CA and FGFR1 genetic results from the literature review is given in Table 2.

**Treatment**

Currently, surgery is the mainstay of treatment. Because RGNT has historically been thought of as indolent, gross total resection (GTR) is typically only attempted if there is very low risk of damaging surrounding structures. Subtotal resection (STR), partial resection (PR), and simple biopsy with observation have all been employed for these tumors due to the risk of doing more harm with unnecessary aggressive removal.\(^{23,37,67}\) Among the cases that reported treatment (116 cases), 62 underwent GTR (53%), 32 underwent STR (28%), 7 underwent a partial resection (6%), and 4 underwent a biopsy only (3%). Other adjunctive treatments included radiotherapy (9 cases, 8%) and chemotherapy (4 cases, 3%). Though there is not a large enough sample size of recurrences to draw significant conclusions regarding the most effective treatment plan, Morris et al. postulate a pattern of delayed recurrence of tumor for patients that receive GTR as opposed to earlier recurrence for those that receive STR.\(^{57}\) Although the results of our analysis are not quite as striking, the average time to tumor recurrence for patients that underwent GTR was longer at 6.17 years compared to 2.92 years to recurrence for patients that underwent STR. However, even with this small sample size,
the probability of recurrence approximates 10% with either GTR or STR. Thus, while RGNT might have a more aggressive nature than previously thought, aggressive resection in all cases may not be warranted. Based on the potential for a rapidly progressive clinical course, it is our opinion that gross total resection should be pursued when feasible. Surgical follow-up data for each case, including location and treatment, are displayed in Supplemental Table 1. Recurrence data are summarized in Table 3.

The effectiveness of chemotherapy and radiotherapy as primary or adjunctive therapy remains unclear. These therapies have very rarely been applied to RGNT treatment and typically only in cases of recurrent or disseminated tumors. We identified only one case, described by Morris et al., in which chemotherapy was not effective at limiting the rapid spread of RGNT. In this case, 4 cycles of vincristine, etoposide, and carboplatin were given after the initial resection, which resulted in stable tumor remnant for 2 years. When the tumor recurred and extended into the spinal cord, another chemotherapy regimen was attempted using weekly vinblastine for 6 months, which did not halt the progression of tumor growth. However, all other reported uses of chemotherapy (3) and all reported uses of radiotherapy (9) in cases of RGNT have yielded stable tumor remnant and no recurrence for varying lengths of follow-up.

### Conclusion

RGNT is a rare low-grade central nervous tumor usually localized within the fourth ventricle that is typically managed with surgical resection and often remains stable at follow-up. We present a case with stable tumor size and character on imaging for 3 years and sudden progression with a development of a secondary lesion 3 years later. Upon review of the literature, there are many examples of rapid progression, recurrences, and even malignant transformation, calling RGNT’s indolent reputation into question. There is insufficient evidence to support adjunctive treatment such as chemotherapy and radiotherapy in prevention of progression.

### Table 2. Genetics Table

|        | Cachia 2014 | Ellezam 2012 | Ellezam 2012 | Eye 2017 | Kitamura 2018 | Kitamura 2018 | Kitamura 2018 | Lin 2016 | Thommen 2013 |
|--------|-------------|--------------|--------------|----------|---------------|---------------|---------------|----------|-------------|
| PIK3CA | Exon 9: G>A | Exon 9: G>A  | Exon 20: >G  | Wild type| Wild type     | Wild type     | Exon 20: A>G  | Exon 20: A>G | Exon 20: A>G |
|        | E545K       | H1047R       | H1047R       | vs. A>G  | H1047R        | H1047R        | H1047R        | H1047R   | H1047R      |
| FGFR1  | NT          | NT           | NT           | NT       | NT            | NT            | Exon 12: C>A  | Exon 12: C>A | NT          |
|        |             |              |              |          |               |               | N546K         | N546K     |             |

NT, not tested.

### Table 3. Recurrence Analysis Table

| Procedure | Total Cases | Number of Recurrences | Time to Recurrence | Mean Time to Recurrence | Relative % of Recurrences | Paper | Adjunctive Treatment |
|-----------|-------------|-----------------------|--------------------|-------------------------|---------------------------|-------|----------------------|
| GTR       | 62          | 6                     | 10 years           | 6.17 years              | 9.70%                     | Jacques | None                 |
|           |             |                       | 9 years            |                         |                           | Ellezam | None                 |
|           |             |                       | 7 years            |                         |                           | Kwon    | None                 |
|           |             |                       | 4 years            |                         |                           | Ramos   | None                 |
|           |             |                       | 4 years            |                         |                           | Ellezam | None                 |
|           |             |                       | 3 years*           |                         |                           | Morris  | None                 |
| STR       | 32          | 3                     | 6 years            | 2.92 years              | 9.40%                     | Jayapalan | Chemotherapy |
|           |             |                       | 2 years*           |                         |                           | Morris  | None                 |
|           |             |                       | 9 months           |                         |                           | Thurston| None                 |
| PR        | 7           | 1                     | 4 months           | 4 months                | 14%                       | Yamamoto | None                 |
| Biopsy only | 4           | 2                     | 6 months           | 3.5 months              | 50%                       | Chiba    | None                 |
|           |             |                       | 1 month            |                         |                           | Silveira | None                 |

GTR, gross total resection; PR, partial resection; STR, subtotal resection.

*Same patient. First received STR + chemo, then GTR after initial recurrence.
recurrence, but GTR and STR seem to have similar effectiveness as measured by patient survival and tumor recurrence. Further research is necessary to uncover the pathogenesis and genetic basis of RGNT so that better targeted therapies for aggressive cases that may be developed.

Supplementary Data

Supplementary data are available at Neuro-Oncology Advances online.

Keywords

case report | Rosette-forming glioneuronal tumor | systematic review

Acknowledgments

Author contributions: Project administration: C.A.G.; Writing—original draft: C.P.W. and A.R.C.; Writing—review and editing: C.P.W., A.R.C., P.E.P., H.H.S., C.K.M., and C.A.G.; Resources: P.E.P., H.H.S., S.S., T.M., and J.E.P.

Conflict of interest statement. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. There are no competing interests with regards to this project.

References

1. Komori T, Scheithauer BW, Hirose T. A rosette-forming glioneuronal tumor of the fourth ventricle: infratentorial form of dysmyeloplastic neuroepithelial tumor? Am J Surg Pathol. 2002;26(5):582–591.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.
3. Wen PY, Huse JT. 2016 World Health Organization classification of central nervous system tumors. Continuum (Minneap Minn). 2017;23(6, Neuro-oncology):1531–1547.
4. Xiong J, Liu Y, Chu SG, et al. Rosette-forming glioneuronal tumor of the septum pellucidum with extension to the supratentorial ventricles: rare case with genetic analysis. Neuropathology. 2012;32(3):301–305.
5. Solis OE, Mehta RI, Lai A, et al. Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. J Neurooncol. 2011;102(3):477–484.
6. Yamamoto T, Matsubara T, Satomi K, et al. Rosette-forming glioneuronal tumor originating in the hypothalamus. Brain Tumor Pathol. 2015;32(4):291–296.
7. Scheithauer BW, Silva AI, Ketterling RP, Pula JH, Lininger JR, Krinock MJ. Rosette-forming glioneuronal tumor: report of a chiasmal-optic nerve example in neurofibromatosis type 1: special pathology report. Neurosurgery. 2009;64(4):E771–2; discussion E772.
8. Bharadwaj R, Chickabasaviah YT, Rao S, et al. Rosette-forming glioneuronal tumor in the optic pathway of a child. J Pediatr Hematol Oncol. 2019;42(7):655–658.
9. Aman M, Inoue R, Ishii K, et al. A rosette-forming glioneuronal tumor of the spinal cord: the first case of a rosette-forming glioneuronal tumor originating from the spinal cord. Hum Pathol. 2009;40(6):889–901.
10. Collin A, Adle-Biassette H, Lecler A. Rosette-forming glioneuronal tumor of spinal cord. World Neurosurg. 2018;119:242–243.
11. Duan L, Zhang Y, Fu W, Geng S. Rosette-forming glioneuronal tumor originating from the spinal cord: report of 2 cases and literature review. World Neurosurg. 2017;98:875.e1–875.e7.
12. Adachi J, Nishikawa R, Hirose T, Matsutani M. Mixed neuronal-glial tumor of the fourth ventricle and successful treatment of post-operative mutism with bromocriptine: case report. Surg Neurol. 2005;63(4):375–379.
13. Albanese A, Mangiola A, Pompucci A, et al. Rosette-forming glioneuronal tumour of the fourth ventricle: report of a case with clinical and surgical implications. J Neurooncol. 2005;71(2):195–197.
14. Allenon KS, O’Donovan DG, Jena R, Cross JJ, Santarius TS. Rosette-forming glioneuronal tumor with dissemination throughout the ventricular system: a case report. Clin Neuropathol. 2015;34(2):64–69.
15. Ainaami I, Aronyk K, Lu JD, Johnson ES, O’Kelly C. Rosette-forming glioneuronal tumors in the posterior third ventricle. Can J Neurol Sci. 2013;40(6):885–888.
16. Alturkustani M, Ang LC. Rosette-forming glioneuronal tumour of the fourth ventricle: report in a NF1 patient. Can J Neurol Sci. 2012;39(1):95–96.
17. Arai A, Sasayama T, Tamaki M, et al. Rosette-forming glioneuronal tumor of the fourth ventricle—case report. Neurol Med Chir (Tokyo). 2010;50(3):224–228.
18. Bera G, Das A, Chatterjee S, Chatterjee U. Rosette-forming glioneuronal tumor: a rare posterior fossa tumor in an adolescent. J Pediatr Neurosci. 2017;12(2):168–171.
19. Bauriat PA, Taziedde-Espariat A, Pages M, Varlet P, Di Rocco F. Rosette-forming glioneuronal tumor outside the fourth ventricle: a case-based update. Childs Nerv Syst. 2016;32(1):65–68.
20. Bidinotto LT, Scapulatempo-Neto C, Mackay A, et al. Molecular profiling of a rare rosette-forming glioneuronal tumor arising in the spinal cord. PLoS One. 2015;10(9):e0137680.
21. Cabezas SG, Blanch RS, Sanchez-Sanchez R, Eito AP. Rosette-forming glioneuronal tumour (RGNT) of the fourth ventricle: a highly aggressive case. Brain Tumor Pathol. 2015;32(2):124–130.
22. Cachia D, Prado MP, Theeler B, Hamilton J, McCutcheon I, Fuller GN. Synchronous rosette-forming glioneuronal tumor and diffuse astrocytoma with molecular characterization: a case report. Clin Neuropathol. 2014;33(6):407–411.
23. Cebula H, Chibbaro S, Santin MN, Kremer S, Chaussemy D, Proust F. Thalamic rosette-forming a glioneuronal tumor in an elderly patient: Case report and literature review. Neurochirurgie. 2016;62(1):60–63.
24. Chen SY, Wang W, Wang LM, et al. Glioneuronal tumours with features of rosette-forming glioneuronal tumours of the fourth ventricle and dysmyeloplastic neuroepithelial tumours: a report of three cases. Histopathology. 2016;68(3):379–387.
25. Chiba K, Aihara Y, Eguchi S, Tanaka M, Komori T, Okada Y. Rosette-forming glioneuronal tumor of the fourth ventricle with neurocytoma component. Childs Nerv Syst. 2014;30(2):351–356.
26. Damodaran O, Robbins P, Shivapathasundram G, Bynevelt M, Lee GF. Rosette-forming glioneuronal tumor of the fourth ventricle: surgery complicated by cerebellar mutism in an elderly patient. Neurosurg Q. 2013;23(2):122–126.
Kitamura Y, Komori T, Shibuya M, et al. Comprehensive genetic character-
ization of rosette-forming glioneuronal tumors: independent compo-
min analysis by tissue microdissection. Brain Pathol. 2018;28(1):87–93.

Kumar M, Samant R, Ramakrishniah R, et al. Rosette-forming glioneuronal
tumor of the fourth ventricle. Radiol Case Rep. 2013;8(1):740.

Kwon SM, Kim JH, Byun J, et al. Malignant transformation of a
rosette-forming glioneuronal tumor to glioblastoma. World Neurosurg.
2019;130:271–275.

Li YM, Li WO, Pan Y, et al. Rosette-forming glioneuronal tumor of the
fourth ventricle with previous intratumoral haemorrhage: case report and
review of the literature. J Int Med Res. 2009;37(3):958–966.

Lin FY, Bergstrom K, Person R, et al. Integrated tumor and germline
whole-exome sequencing identifies mutations in MAPK and PI3K
pathway genes in an adolescent with rosette-forming glioneuronal
tumor of the fourth ventricle. Cold Spring Harb Mol Case Stud.
2016;2(5):a010577.

Luan S, Zhuang D, Sun L, Huang FP. Rosette-forming glioneuronal
tumor (RGNT) of the fourth ventricle: case report and review of literature. Clin
Neuro Neurosurg. 2010;112(4):362–364.

Maiti TK, Arimappamagan A, Mahadevan A, Yasha TC, Pandey P,
Santosh V. Rare pathologies in the posterior third ventricular region in
children: case series and review. Pediatr Neurosurg. 2015;50(1):42–47.

Makita K, Ohta T, Yamamura S, et al. Gene alteration of rosette-
forming glioneuronal tumor in a suprasellar lesion. Int J Clin Exp Med.
2016;9(3):6873–6881.

Marhold F, Preusser M, Dietrich W, Prayer D, Czeh T. Clinicoradiological
features of rosette-forming glioneuronal tumor (RGNT) of the fourth
ventricle: report of four cases and literature review. J Neurooncol.
2008;90(3):301–308.

Matyja E, Grajkowska W, Kunert P, Marchel A. A peculiar histopatho-
logical form of dysembryoplastic neuroepithelial tumor with separated
pilocytic astrocytoma and rosette-forming glioneuronal tumor compo-
nents. Neuropathology. 2014;34(5):491–498.

Morris C, Prudowsky ZD, Shetty V, et al. Rosette-forming glioneuronal
tumor of the fourth ventricle in children: case report and literature
review. World Neurosurg. 2017;104:1045.e9–1045.e16.

Nair AR, Gopalakrishnan CV, Kapilamoorthy TR, Radhakrishnan N.
Rosette forming glioneuronal tumor of the fourth ventricle in squash
cytology smear. J Cytol. 2014;31(4):215–217.

Ogut B, Memis L, Emmez OH, Oner AY, Uluglu O. Rosette forming
glioneuronal tumor of fourth ventricle: a case report. Virchows Arch.
2015;467:S210.

Pimentel J, Resende M, Vaz A, et al. Rosette-forming glioneuronal
tumor: pathology case report. Neurosurgery. 2008;62(5):E1162–3; dis-
cussion E1163.

Podlesek D, Geiger K, Hendry DJ, Shackert G, Krex D. Rosette-forming
glioneuronal tumor of the fourth ventricle in an elderly patient. J
Neurooncol. 2011;103(3):727–731.

Pradhan R, Mondal S, Pal S, Chatterjee S, Banerjee A, Bhattacharyya D.
Rosette-forming glioneuronal tumor of the fourth ventricle. Neurol India.
2009;57(5):1167–1177.

Rainov NG, Wagner T, Heidecke V. Rosette-forming glioneuronal tumor
of the fourth ventricle. Cent Eur Neurosurg. 2010;71(4):219–221.

Ramos AA, Vega IF, Batista KP, Fernandez VM, Sanchez CR, Vega MAA.
Rosette-forming glioneuronal tumor of the fourth ventricle. Not always
a foreseeable development. Contemp Oncol (payo). 2018;22(4):270–274.

Sekar A, Rudrappa S, Gopal S, Ghosal N, Rai A. Rosette-forming
glioneuronal tumor in opticochiasmatic region-novel entity in new loca-
tion. World Neurosurg. 2019;125:253–256.

Shah MN, Leonard JR, Perry A. Rosette-forming glioneuronal tumors of
the posterior fossa. J Neurosurg Pediatr. 2010;5(1):98–103.

Sharma P, Swain M, Padua MD, Ranjan A, Lath R. Rosette-
forming glioneuronal tumors: a report of two cases. Neurol India.
2011;59(2):276–280.
68. Sieg EP, Payne R, Langan S, Specht CS. Case report: a rosette-forming glioneuronal tumor in the tectal plate in a patient with neurofibromatosis type I. Cuneus. 2016;8(11):e857.

69. Silveira L, DeWitt J, Thomas A, Tranmer B. Disseminated rosette-forming glioneuronal tumor with spinal drop metastasis, a uniquely aggressive presentation of rare tumor. World Neurosurg. 2019;132:7–11.

70. Simmons DB, Clark ME, Mathis DA, Sladky JH. Rosette-forming glioneuronal tumour in a patient with multiple sclerosis. Histopathology. 2015;67(5):751–753.

71. Sumitomo N, Ishiyama A, Shibuya M, et al. Intractable epilepsy due to a rosette-forming glioneuronal tumor with a dysgenetic polymicrogyric background. Neuropathology. 2018;38(3):300–304.

72. Tan CC, Gonzales M, Veitch A. Clinical implications of the infratentorial rosette-forming glioneuronal tumor: case report. Neurosurgery. 2008;63(1):E175–6; discussion E176.

73. Tanaka F, Matsukawa M, Kogue R, et al. A case of a rosette-forming glioneuronal tumor arising from the pons with disappearance of contrast enhancement. Radiol Case Rep. 2019;14(8):899–902.

74. Thommen F, Hewer E, Schäfer SC, Vassella E, Kappeler A, Vajtai I. Rosette-forming glioneuronal tumor of the cerebellum in statu nascendi: an incidentally detected diminutive example indicates derivation from the internal granule cell layer. Clin Neuropathol. 2013;32(5):370–376.

75. Thurston B, Gunny R, Anderson G, et al. Fourth ventricle rosette-forming glioneuronal tumor in children: an unusual presentation in an 8-year-old patient, discussion and review of the literature. Childs Nerv Syst. 2013;29(5):839–847.

76. Vajtai I, Arnold M, Kappeler A, et al. Rosette-forming glioneuronal tumor of the fourth ventricle: report of two cases with a differential diagnostic overview. Pathol Res Pract. 2007;203(8):613–619.

77. Wang Y, Xiong J, Chu SG, et al. Rosette-forming glioneuronal tumor: report of an unusual case with intraventricular dissemination. Acta Neuropathol. 2008;116(6):813–819.

78. Xiong J, Ding L, Chen H, Chen H, Wang Y. Mixed glioneuronal tumor: a dysgenetic neoplasm with rosette-forming glioneuronal tumor component. Neuropathology. 2013;33(4):431–435.

79. Xu J, Yang Y, Liu Y, et al. Rosette-forming glioneuronal tumor in the pineal gland and the third ventricle: a case with radiological and clinical implications. Quant Imaging Med Surg. 2012;2(3):227–231.

80. Yapıcıer Ö, Demir MK, Jaafar E, Bozbuğ M. Mesial temporal lobe rosette-forming glioneuronal tumor: an unusual location for a rare tumor. Acta Neurol Belg. 2020;120(2):465–467.

81. Yin B, Liu L, Chen XR, Li K, Geng DY. Rosette-forming glioneuronal tumor of the fourth ventricle. J Neurol. 2012;29(2):129–130.

82. Zhang J, Babu R, McLendon RE, Friedman AH, Adamson C. A comprehensive analysis of 41 patients with rosette-forming glioneuronal tumors of the fourth ventricle. J Clin Neurosci. 2013;20(3):335–341.

83. Chakraborti S, Mahadevan A, Govindan A, et al. Rosette-forming glioneuronal tumor – evidence of stem cell origin with biphenotypic differentiation. Virchows Arch. 2012;461(5):581–588.

84. Sievers P, Appay R, Schrimpff D, et al. Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. Acta Neuropathol. 2019;138(3):497–504.

85. Yamada S, Nobusawa S, Yamazaki T, et al. An epilepsy-associated glioneuronal tumor with mixed morphology harboring FGFR1 mutation. Pathol Int. 2019;69(6):372–377.

86. Halfpenny A, Ferris SP, Grafe M, et al. A case of recurrent epilepsy-associated rosette-forming glioneuronal tumor with anaplastic transformation in the absence of therapy. Neuropathology. 2019;39(5):389–393.